LIVE DATABASE v1.0
返回公司目录
COMPANY PROFILE / #1515

Adaptyv

Lausanne, SwitzerlandVenture Capital-Backed
官网
OVERVIEW

Developer of an automated protein validation and experimental data management platform designed for protein research and biological design workflows. The company's platform helps to submit protein sequences, select experimental assay types, manage wet-lab experiments, track experiment progress, access analyzed and labeled experimental datasets, export raw results, integrate data through APIs, and support iterative model development through automated laboratory testing and protein synthesis, enabling biotechnology, pharmaceutical, and protein engineering teams to obtain experimental validation data and manage research workflows.

已融资51.21
最新估值218.00
员工数25
成立年份2020

公司概况

Companies
Adaptyv
Description
Developer of an automated protein validation and experimental data management platform designed for protein research and biological design workflows. The company's platform helps to submit protein sequences, select experimental assay types, manage wet-lab experiments, track experiment progress, access analyzed and labeled experimental datasets, export raw results, integrate data through APIs, and support iterative model development through automated laboratory testing and protein synthesis, enabling biotechnology, pharmaceutical, and protein engineering teams to obtain experimental validation data and manage research workflows.
HQ Location
Lausanne, Switzerland
Year Founded
2020
Keywords
ai in healthcare, antibodies test, biotechnology center, biotechnology device, computational system, nanofluidic sample, protein engineering technology, synthetic biology study
Competitors
ATUM (Biotechnology), Takara Bio USA, Mayflower Bioscience, Cell Technology, BioVision, Integral Molecular, Novus Biologicals, Assay Biotech, BioLegend, BPS Bioscience, Eurofins Calixar, Creative BioMart, DiaCarta, Immunomic Therapeutics, Apexigen
Ownership Status
Privately Held (backing)
Company Financing Status
Venture Capital-Backed

融资与估值

Total Raised
51.21
First Financing Date
01-Jan-2020
First Financing Size
First Financing Valuation
Last Financing Date
26-Aug-2026
Last Financing Deal Type
Later Stage VC
Last Financing Size
40.00
Last Financing Valuation
218.00
Last Financing Status
Completed
Last Known Valuation
218.00
Last Known Valuation Date
26-Aug-2026
Last Known Valuation Deal Type
Later Stage VC
Valuation Estimate
220.93
Valuation Estimate Growth Rate
1.34%
Active Investors
ACE & Company (Geneva), ACE Ventures (Geneva), Acequia Capital, Axial (San Francisco), Biopole, byFounders, Ecole Polytechnique Federale de Lausanne, Founderful, Founderful Campus, Founders, Inc, Hawktail, Highland Europe, iGem Startups, LongGame Ventures, Neer Venture Partners, Rheingau Founders, S2S Ventures, S2S Ventures (South Africa), Unruly Capital, Venture Kick, Y Combinator
# Active Investors
21
Acquirers

团队与联系人

Employees
25
Employee Growth %
13.64%
Employee History
2026: 25, 2025: 22, 2024: 15, 2023: 14, 2022: 9, 2021: 4
Primary Contact
Julian Englert
Primary Contact Title
Co-Founder & Chief Executive Officer
Primary Contact Email
julian@adaptyvbio.com
Primary Contact Phone

增长与经营

Revenue
Revenue Growth %
Growth Rate
0.95%
Growth Rate % Change
Growth Rate Percentile
97
Size Multiple
6.25x
Size Multiple % Change
0.00%
Size Multiple Change
0.00x
Size Multiple Percentile
86
Majestic Referring Domains
244
SimilarWeb Unique Visitors
1,367
SimilarWeb Unique Visitors Change
57
SimilarWeb Growth Rate
SimilarWeb Growth Rate Percentile
Success Probability Over Time – 1 Year
6%
Success Probability Over Time – 3 Year
12%
Success Probability Over Time – 5 Year
22%
记录来源:public.companies · 原始序号 #1515 · 所有字段均按数据库原值展示。